Results 8,621-8,640 of 12,403 for speaker:Louise O'Reilly

Written Answers — Department of Health: Obesity Strategy (27 Nov 2018)

Louise O'Reilly: 462. To ask the Minister for Health the way in which the obesity policy implementation oversight group will engage with the recommendations of the Oireachtas Committee on Children and Youth Affairs's report on childhood obesity; and if he will make a statement on the matter. [49556/18]

Written Answers — Department of Health: Obesity Strategy (27 Nov 2018)

Louise O'Reilly: 463. To ask the Minister for Health the status of the way in which Action 2.1 of A Healthy Weight for Ireland, the Obesity Policy and Action Plan will be advanced; and if he will make a statement on the matter. [49557/18]

Written Answers — Department of Health: Obesity Strategy (27 Nov 2018)

Louise O'Reilly: 464. To ask the Minister for Health the outcomes that have come from the stakeholder forum on the built environment that took place on 21 November 2018; if a report will be compiled on the recommendations from the event; and if he will make a statement on the matter. [49558/18]

Written Answers — Department of Health: Obesity Strategy (27 Nov 2018)

Louise O'Reilly: 465. To ask the Minister for Health the details on working groups to be established to design, enhance and deliver healthier environments after the stakeholder forum on the built environment that took place on 21 November 2018; if the obesity policy and action plan will examine developing a guidance document for health and environmental planning; and if he will make a statement on the matter....

Written Answers — Department of Health: Health Services Provision (27 Nov 2018)

Louise O'Reilly: 424. To ask the Minister for Health the new sexual health clinics or testing services opened or expanded since the publication of the National Sexual Health Strategy 2015 to 2020; and if he will make a statement on the matter. [49270/18]

Written Answers — Department of Finance: Insurance Industry (22 Nov 2018)

Louise O'Reilly: 20. To ask the Minister for Finance the steps he will take to ensure that residents affected by the liquidation of the structural warranty of an underwriter (details supplied) are not unfairly affected; and his plans to deal with this issue. [48604/18]

Written Answers — Department of Health: Patient Safety (22 Nov 2018)

Louise O'Reilly: 150. To ask the Minister for Health if his attention has been drawn to the fact that a patient with tuberculosis was not isolated while at University Hospital Galway; and if disclosures of this incident have been made to him. [48774/18]

Older People: Motion [Private Members] (21 Nov 2018)

Louise O'Reilly: Home supports, home help packages and home help hours are some of the most vital services provided by the State. This was evident to me as someone who represented home help workers a number of years ago when the Fianna Fáil-led Government brought in the moratorium on recruitment. As bad as things were, home help workers were exempted because it was a good value for money service....

Ceisteanna Eile - Other Questions: Defence Forces Recruitment (21 Nov 2018)

Louise O'Reilly: 71. To ask the Taoiseach and Minister for Defence the steps being taken to address the retention crisis in the Defence Forces; when the target staffing level of the Defence Forces will be met; and if he will make a statement on the matter. [47797/18]

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Louise O'Reilly: I thank the witnesses for coming in this morning. We have talked a little about bringing transparency into the process but we keep coming up against the barrier of commercial sensitivity. Is there any country that does it better? Could we look to Scotland or replicate what is being done in any other country? Do we need to reinvent the wheel if another country has gone to the trouble of...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Louise O'Reilly: The challenge is to bring the voices in and to recognise that when the answer is "No" it is because the drug is not going to work and not because the system is just giving a blanket "No". Patients feel they are not involved in the process.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Louise O'Reilly: I did not mention any company but it was high-profile-----

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Louise O'Reilly: It looked like a map of an underground from somewhere.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Louise O'Reilly: It was very convoluted.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Louise O'Reilly: Mr. Watt said he observed one of the PACE meetings in Scotland. Would it be fair to say be advocates were there on an equal footing and their contribution was-----

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Louise O'Reilly: There is probably more said by what is left out than what is in the public domain.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Louise O'Reilly: I thank the witnesses for being here. We respect and appreciate the job the witnesses do and we acknowledge that very often they are portrayed as the bad guys but sometimes they do not help their own cause. Patients come to us because they want to know the status of their approvals. They should not have to contact their local public representatives to get that information. It should be...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Louise O'Reilly: My question was about moving along through the process.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Louise O'Reilly: The NCPE is not the only organisation involved.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)

Louise O'Reilly: I acknowledge that but the witnesses are collectively representing the Department and the HSE. The progress is being tracked through all committees.